7-Hydroxymitragynine Causes Respiratory Depression Like Morphine; Mitragynine Does Not

Why it matters

As kratom products increasingly contain high concentrations of synthesized 7-hydroxymitragynine (7-HMG), this study clarifies that 7-HMG poses serious respiratory risks similar to classical opioids, while kratom's main compound mitragynine appears to be safer. The findings directly inform regulatory decisions about concentrated kratom products.

The big picture

Despite kratom's growing use as an opioid alternative, the respiratory safety profiles of its key alkaloids have remained poorly understood. Manufacturers now market 7-HMG products at 14-25 mg per serving with purity as high as 98%—far exceeding naturally occurring levels in kratom leaves (typically <0.1%). This University of Florida study provides the first comprehensive comparison of respiratory effects between mitragynine (MG) and 7-hydroxymitragynine (7-HMG) in awake rats, with and without naloxone reversal.

Key findings

• 7-HMG induced dose-dependent respiratory depression comparable to morphine, with 4.5-fold greater potency than morphine in reducing breathing
• Mitragynine unexpectedly increased respiratory frequency rather than depressing it
• Naloxone fully reversed respiratory depression from both morphine and 7-HMG
• Mitragynine's respiratory stimulant effects were NOT reversed by naloxone, suggesting it works through non-opioid mechanisms
• Semisynthetic 7-HMG products containing up to 98% purity are now widely marketed despite the opioid-level respiratory risks

What they say

According to the authors, "These findings demonstrate that 7-HMG exhibits significant respiratory depressant properties similar to classical opioids, and importantly, such depressant effects are effectively antagonized by naloxone. Conversely, MG exerts respiratory stimulant effects through mechanisms independent of opioid receptor pathways."

Bottom line

Concentrated 7-HMG products carry true opioid-level respiratory risks reversible by naloxone—while natural kratom's primary compound mitragynine appears to have a fundamentally different, safer respiratory profile.